vs

Side-by-side financial comparison of AIR INDUSTRIES GROUP (AIRI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

AIR INDUSTRIES GROUP is the larger business by last-quarter revenue ($12.8M vs $12.5M, roughly 1.0× Avidity Biosciences, Inc.). AIR INDUSTRIES GROUP runs the higher net margin — 1.2% vs -1398.3%, a 1399.5% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -14.1%). AIR INDUSTRIES GROUP produced more free cash flow last quarter ($-902.0K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -4.5%).

Mitsubishi Heavy Industries, Ltd. is a Japanese multinational engineering, electrical equipment and electronics corporation headquartered in Tokyo, Japan. MHI is one of the core companies of the Mitsubishi Group and its automobile division is the predecessor of Mitsubishi Motors.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

AIRI vs RNA — Head-to-Head

Bigger by revenue
AIRI
AIRI
1.0× larger
AIRI
$12.8M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+448.1% gap
RNA
434.0%
-14.1%
AIRI
Higher net margin
AIRI
AIRI
1399.5% more per $
AIRI
1.2%
-1398.3%
RNA
More free cash flow
AIRI
AIRI
$156.0M more FCF
AIRI
$-902.0K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-4.5%
AIRI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AIRI
AIRI
RNA
RNA
Revenue
$12.8M
$12.5M
Net Profit
$149.0K
$-174.4M
Gross Margin
14.3%
Operating Margin
0.7%
-1513.5%
Net Margin
1.2%
-1398.3%
Revenue YoY
-14.1%
434.0%
Net Profit YoY
126.9%
-117.0%
EPS (diluted)
$0.08
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AIRI
AIRI
RNA
RNA
Q4 25
$12.8M
Q3 25
$10.3M
$12.5M
Q2 25
$12.7M
$3.8M
Q1 25
$12.1M
$1.6M
Q4 24
$14.9M
$3.0M
Q3 24
$12.6M
$2.3M
Q2 24
$13.6M
$2.0M
Q1 24
$14.1M
$3.5M
Net Profit
AIRI
AIRI
RNA
RNA
Q4 25
$149.0K
Q3 25
$-44.0K
$-174.4M
Q2 25
$-422.0K
$-157.3M
Q1 25
$-988.0K
$-115.8M
Q4 24
$-554.0K
$-102.3M
Q3 24
$-404.0K
$-80.4M
Q2 24
$298.0K
$-70.8M
Q1 24
$-706.0K
$-68.9M
Gross Margin
AIRI
AIRI
RNA
RNA
Q4 25
14.3%
Q3 25
22.3%
Q2 25
16.0%
Q1 25
16.8%
Q4 24
16.4%
Q3 24
15.5%
Q2 24
19.5%
Q1 24
13.6%
Operating Margin
AIRI
AIRI
RNA
RNA
Q4 25
0.7%
Q3 25
3.1%
-1513.5%
Q2 25
0.1%
-4448.7%
Q1 25
-6.1%
-8360.9%
Q4 24
-0.7%
-4069.6%
Q3 24
0.5%
-4200.9%
Q2 24
5.5%
-4040.4%
Q1 24
-1.8%
-2178.6%
Net Margin
AIRI
AIRI
RNA
RNA
Q4 25
1.2%
Q3 25
-0.4%
-1398.3%
Q2 25
-3.3%
-4089.3%
Q1 25
-8.1%
-7360.0%
Q4 24
-3.7%
-3439.5%
Q3 24
-3.2%
-3441.7%
Q2 24
2.2%
-3461.8%
Q1 24
-5.0%
-1943.4%
EPS (diluted)
AIRI
AIRI
RNA
RNA
Q4 25
$0.08
Q3 25
$-0.01
$-1.27
Q2 25
$-0.11
$-1.21
Q1 25
$-0.27
$-0.90
Q4 24
$-0.16
$-0.80
Q3 24
$-0.12
$-0.65
Q2 24
$0.08
$-0.65
Q1 24
$-0.21
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AIRI
AIRI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
$5.9M
Stockholders' EquityBook value
$19.2M
$1.9B
Total Assets
$58.3M
$2.1B
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AIRI
AIRI
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$186.0K
$370.2M
Q2 24
$575.8M
Q1 24
$225.0K
$471.4M
Total Debt
AIRI
AIRI
RNA
RNA
Q4 25
$5.9M
Q3 25
Q2 25
$6.4M
Q1 25
$6.6M
Q4 24
$5.2M
Q3 24
$5.4M
Q2 24
Q1 24
$4.9M
Stockholders' Equity
AIRI
AIRI
RNA
RNA
Q4 25
$19.2M
Q3 25
$18.8M
$1.9B
Q2 25
$15.3M
$1.2B
Q1 25
$15.3M
$1.3B
Q4 24
$14.9M
$1.4B
Q3 24
$14.7M
$1.5B
Q2 24
$14.9M
$1.2B
Q1 24
$14.5M
$830.9M
Total Assets
AIRI
AIRI
RNA
RNA
Q4 25
$58.3M
Q3 25
$58.0M
$2.1B
Q2 25
$50.4M
$1.4B
Q1 25
$48.4M
$1.5B
Q4 24
$51.0M
$1.6B
Q3 24
$50.4M
$1.6B
Q2 24
$1.3B
Q1 24
$50.3M
$951.5M
Debt / Equity
AIRI
AIRI
RNA
RNA
Q4 25
0.30×
Q3 25
Q2 25
0.42×
Q1 25
0.43×
Q4 24
0.35×
Q3 24
0.37×
Q2 24
Q1 24
0.33×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AIRI
AIRI
RNA
RNA
Operating Cash FlowLast quarter
$-598.0K
$-156.2M
Free Cash FlowOCF − Capex
$-902.0K
$-156.9M
FCF MarginFCF / Revenue
-7.0%
-1257.6%
Capex IntensityCapex / Revenue
2.4%
5.7%
Cash ConversionOCF / Net Profit
-4.01×
TTM Free Cash FlowTrailing 4 quarters
$-4.7M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AIRI
AIRI
RNA
RNA
Q4 25
$-598.0K
Q3 25
$-2.6M
$-156.2M
Q2 25
$345.0K
$-199.7M
Q1 25
$1.5M
$-124.8M
Q4 24
$-184.0K
$-99.9M
Q3 24
$174.0K
$-65.6M
Q2 24
$566.0K
$-65.0M
Q1 24
$-232.0K
$-70.4M
Free Cash Flow
AIRI
AIRI
RNA
RNA
Q4 25
$-902.0K
Q3 25
$-3.5M
$-156.9M
Q2 25
$-551.0K
$-203.0M
Q1 25
$308.0K
$-128.6M
Q4 24
$-985.0K
$-103.8M
Q3 24
$-95.0K
$-67.3M
Q2 24
$-554.0K
$-65.5M
Q1 24
$-343.0K
$-71.3M
FCF Margin
AIRI
AIRI
RNA
RNA
Q4 25
-7.0%
Q3 25
-34.2%
-1257.6%
Q2 25
-4.4%
-5277.1%
Q1 25
2.5%
-8174.3%
Q4 24
-6.6%
-3491.0%
Q3 24
-0.8%
-2881.8%
Q2 24
-4.1%
-3204.6%
Q1 24
-2.4%
-2012.3%
Capex Intensity
AIRI
AIRI
RNA
RNA
Q4 25
2.4%
Q3 25
8.8%
5.7%
Q2 25
7.1%
86.9%
Q1 25
10.0%
238.6%
Q4 24
5.4%
131.7%
Q3 24
2.1%
72.9%
Q2 24
8.3%
26.0%
Q1 24
0.8%
25.8%
Cash Conversion
AIRI
AIRI
RNA
RNA
Q4 25
-4.01×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
1.90×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AIRI
AIRI

Military$7.4M58%
Other$5.4M42%

RNA
RNA

Segment breakdown not available.

Related Comparisons